| Name | Shield Therapeutics |
|---|---|
| Epic | STX |
| Isin | GB00BYV81293 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 2.35p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £24.48 | Debt ratio | n/a |
| Shares in issue | 782.06 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -170.14 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -5 | 52-week high / low | 1.23p / 6.86p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Shield Therapeutics |
|---|---|
| Address | Northern Design Centre, Baltic Business Quarter, Gateshead Quays, United Kingdom, NE8 3DF |
| Telephone | +44 (0) 191 511 8500 |
| Website | http://www.shieldtherapeutics.com/ |
| Director | Position |
|---|---|
| Dr Christian Schweiger | Non-Executive Director |
| Mr Hans-Peter Hasler | Non-Executive Chairman |
| Mrs Fabiana Lacerca Allen | Independent Non-Executive Director |
| Mr Peter Llewellyn-Davies | Independent Non-Executive Director |
| Mr Anders Lundstrom | Interim CEO |
| Assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | 16.86 | 14.21 | 26.85 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 17.54 | 14.45 | 27.16 |
| Inventory / work in progress | 3.2 | 1.76 | 1.64 |
| Trade and other receivables | 13.5 | 6.49 | 2.93 |
| Cash and equivalents | 13.95 | 3.4 | 12.12 |
| Other current assets and asset held for resale | 0.61 | 0.53 | 0.58 |
| Total of all assets | 48.8 | 26.62 | 44.41 |
| Liabilities £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 13.73 | 12.83 | 3.72 |
| Long term liabilities | 20.03 | 7.24 | n/a |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 33.77 | 20.07 | 3.72 |
| Net assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 15.03 | 6.54 | 40.69 |
| Equity £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 15.01 | 5.37 | 3.24 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -233.52 | -201.11 | -106.94 |
| Share premium account | 198.76 | 169.48 | 114.58 |
| Total equity | 15.03 | 6.54 | 40.69 |
| Income £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -31.33 | -49.75 | -20.29 |
| Pre-tax profit | -32.38 | -49.43 | -19.91 |